42 related articles for article (PubMed ID: 33202495)
1. [Clinical analysis of 12 cases of acute myeloid leukemia complicated with synchronous primary solid tumor].
Mi RH; Dang HB; Chen L; Han YL; Wang MF; Zhang YL; Chen L; Li DB; Wei XD
Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3323-3327. PubMed ID: 33202495
[No Abstract] [Full Text] [Related]
2. [Analysis of the clinical characteristics of acute myeloid leukemia related to the treatment of hematological and solid tumors].
Jiao Y; Jiang YH; Liu B; Mi RH; Bi LJ; Xu QX
Zhonghua Zhong Liu Za Zhi; 2024 Jan; 46(1):86-95. PubMed ID: 38246784
[No Abstract] [Full Text] [Related]
3. Clinical analysis of multiple primary gastrointestinal malignant tumors: A 10-year case review of a single-center.
Zhu CL; Peng LZ
World J Gastrointest Oncol; 2024 Apr; 16(4):1204-1212. PubMed ID: 38660651
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience.
Mirza AS; Yun S; Ali NA; Shin H; O'Neil JL; Elharake M; Schwartz D; Robinson K; Nowell E; Engle G; Badat I; Brimer T; Kuc A; Sequeira A; Mirza S; Sikaria D; Vera JD; Hackney N; Abusrur S; Jesurajan J; Kuang J; Patel S; Khalil S; Bhaskar S; Beard A; Abuelenen T; Ratnasamy K; Visweshwar N; Komrokji R; Jaglal M
Thromb J; 2019; 17():13. PubMed ID: 31303864
[TBL] [Abstract][Full Text] [Related]
5. [RUNX1 gene mutations are associated with adverse prognosis of patients with acute myeloidleukemia].
Yang Y; Li T; Geng Y; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Nov; 40(11):1601-1606. PubMed ID: 33243739
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.
Antar AI; Otrock ZK; Abou Dalle I; El-Cheikh J; Bazarbachi A
Front Oncol; 2020; 10():596134. PubMed ID: 33224890
[TBL] [Abstract][Full Text] [Related]
7. Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation.
Kamitani I; Saito T; Yokoyama H; Nakano A; Ishii H; Tanoue S; Hattori D; Oshima S; Ishii S; Gunji T; Fukushima R; Katsube A; Shimada T; Nishiwaki K; Dobashi N; Yano S
J Infect Chemother; 2021 Apr; 27(4):639-641. PubMed ID: 33214069
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.
Gebru MT; Wang HG
J Hematol Oncol; 2020 Nov; 13(1):155. PubMed ID: 33213500
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
Scholl S; Fleischmann M; Schnetzke U; Heidel FH
Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
[TBL] [Abstract][Full Text] [Related]
10. Emerging treatment options for patients with high-risk myelodysplastic syndrome.
Bewersdorf JP; Carraway H; Prebet T
Ther Adv Hematol; 2020; 11():2040620720955006. PubMed ID: 33240476
[TBL] [Abstract][Full Text] [Related]
11. Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide.
Turk S; Turk C; Akbar MW; Kucukkaraduman B; Isbilen M; Demirkol Canli S; Malkan UY; Okay M; Ucar G; Sayinalp N; Haznedaroglu IC; Gure AO
PLoS One; 2020; 15(11):e0242497. PubMed ID: 33237942
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity.
Alamón C; Dávila B; García MF; Sánchez C; Kovacs M; Trias E; Barbeito L; Gabay M; Zeineh N; Gavish M; Teixidor F; Viñas C; Couto M; Cerecetto H
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33218150
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Wang H; Bai J; Pei Z; Zhang B; Wang J; Lian X; Song Q
Medicine (Baltimore); 2020 Nov; 99(47):e23265. PubMed ID: 33217852
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer.
Liu Y; Ji X; Kang N; Zhou J; Liang X; Li J; Han T; Zhao C; Yang T
Cell Death Dis; 2020 Nov; 11(11):993. PubMed ID: 33214550
[TBL] [Abstract][Full Text] [Related]
16. MLL-menin and FLT3 inhibitors team up for AML.
Perl AE
Blood; 2020 Nov; 136(21):2369-2370. PubMed ID: 33211832
[No Abstract] [Full Text] [Related]
17. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
Short NJ; Montalban-Bravo G; Hwang H; Ning J; Franquiz MJ; Kanagal-Shamanna R; Patel KP; DiNardo CD; Ravandi F; Garcia-Manero G; Takahashi K; Konopleva M; Daver N; Issa GC; Andreeff M; Kantarjian H; Kadia TM
Blood Adv; 2020 Nov; 4(22):5681-5689. PubMed ID: 33211826
[TBL] [Abstract][Full Text] [Related]
18. New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts.
Lantuejoul S; Fernandez-Cuesta L; Damiola F; Girard N; McLeer A
Transl Lung Cancer Res; 2020 Oct; 9(5):2233-2244. PubMed ID: 33209646
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA as a potential prognostic and predictive biomarker during interventional therapy of unresectable primary liver cancer.
Zhao W; Qiu L; Liu H; Xu Y; Zhan M; Zhang W; Xin Y; He X; Yang X; Bai J; Xiao J; Guan Y; Li Q; Chang L; Yi X; Li Y; Chen X; Lu L
J Gastrointest Oncol; 2020 Oct; 11(5):1065-1077. PubMed ID: 33209498
[TBL] [Abstract][Full Text] [Related]
20. Update on the Treatment of Heavily Pretreated, Relapsed Refractory Multiple Myeloma.
Oncology (Williston Park); 2020 Nov; 34(11):504-507. PubMed ID: 33206992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
